Market Research Logo

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) Overview
Therapeutics Development
Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Stage of Development
Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Therapy Area
Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Indication
Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
Amgen Inc.
Astellas Pharma Inc.
Chiesi Farmaceutici SpA
Fujimoto Pharmaceutical Corporation
Krenitsky Pharmaceuticals Inc.
MedImmune, LLC
NsGene A/S
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
AS-288640100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulranumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NGF for Undisclosed Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NsG-0202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Target NGF for Undisclosed Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Neurotrophic Keratitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Projects
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Featured News & Press Releases
May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain
Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors
Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909
Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug
Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program
Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab
May 12, 2010: Regeneron Provides Initial Data On REGN475
Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010
Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202
Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx
Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains
Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Amgen Inc., H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by Chiesi Farmaceutici SpA, H2 2016
Pipeline by Fujimoto Pharmaceutical Corporation, H2 2016
Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
Pipeline by MedImmune, LLC, H2 2016
Pipeline by NsGene A/S, H2 2016
Pipeline by Pfizer Inc., H2 2016
Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016’, provides in depth analysis on Beta Nerve Growth Factor (Beta NGF or NGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
  • The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;